Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ADIL Adial Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: ADIL
Price (delayed)
$0.685
Market cap
$5.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.46
Enterprise value
$3.05M
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist,
Highlights
The company's EPS has surged by 54% YoY and by 46% QoQ
Adial Pharmaceuticals's net income has increased by 32% from the previous quarter but it has decreased by 2.9% YoY
Adial Pharmaceuticals's quick ratio has shrunk by 80% YoY and by 53% QoQ
ADIL's equity has shrunk by 65% YoY and by 48% QoQ
Key stats
What are the main financial stats of ADIL
Market
Valuations
Earnings
Shares outstanding
7.9M
Market cap
$5.41M
Enterprise value
$3.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.12
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$8.71M
Net income
-$8.95M
EBIT
-$8.95M
EBITDA
-$8.95M
Free cash flow
-$6.88M
Per share
Balance sheet
Liquidity
EPS
-$1.46
EPS diluted
-$1.46
Free cash flow per share
-$1.05
Book value per share
$0.32
Revenue per share
$0
TBVPS
$0.53
Total assets
$3.45M
Total liabilities
$1.32M
Debt
$0
Equity
$2.13M
Working capital
$1.3M
Debt to equity
0
Current ratio
1.99
Quick ratio
1.79
Net debt/EBITDA
0.26
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-177.6%
Return on equity
-218.9%
Return on invested capital
-2,065.9%
Return on capital employed
-420.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADIL stock price
How has the Adial Pharmaceuticals stock price performed over time
Intraday
-0.44%
1 week
-0.7%
1 month
-0.72%
1 year
-52.76%
YTD
-32.18%
QTD
8.01%
Financial performance
How have Adial Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$8.71M
Net income
-$8.95M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 35% year-on-year and by 5% since the previous quarter
Adial Pharmaceuticals's net income has increased by 32% from the previous quarter but it has decreased by 2.9% YoY
Price vs fundamentals
How does ADIL's price correlate with its fundamentals
Growth
What is Adial Pharmaceuticals's growth rate over time
Valuation
What is Adial Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.12
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 54% YoY and by 46% QoQ
ADIL's equity has shrunk by 65% YoY and by 48% QoQ
The stock's price to book (P/B) is 51% more than its last 4 quarters average of 1.4 but 51% less than its 5-year quarterly average of 4.3
Efficiency
How efficient is Adial Pharmaceuticals business performance
ADIL's return on assets is up by 21% since the previous quarter and by 8% year-on-year
The ROIC fell by 20% QoQ
ADIL's ROE is up by 16% QoQ
Dividends
What is ADIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADIL.
Financial health
How did Adial Pharmaceuticals financials performed over time
The company's total assets is 161% higher than its total liabilities
Adial Pharmaceuticals's total liabilities has soared by 135% YoY and by 36% from the previous quarter
Adial Pharmaceuticals's quick ratio has shrunk by 80% YoY and by 53% QoQ
Adial Pharmaceuticals's debt is 100% less than its equity
ADIL's equity has shrunk by 65% YoY and by 48% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.